Ethical considerations of universal vaccination against human papilloma virus

Navarro-Illana, Pedro; Aznar, Justo; Díez-Domingo, Javier
April 2014
BMC Medical Ethics;2014, Vol. 15 Issue 1, p1
Academic Journal
Background From an epidemiological perspective, the practice of universal vaccination of girls and young women in order to prevent human papilloma virus (HPV) infection and potential development of cervical cancer is widely accepted even though it may lead to the neglect of other preventive strategies against cervical cancer. Discussion It is argued that removing the deterrent effect - the fear of developing cancer - could encourage teenage sex. This paper reflects on the ethical legitimacy of the universal vaccination of girls and young women against HPV infection, especially regarding safety issues, the need to vaccinate people who have opted to abstain from sex, the presumption of early onset of sexual relations, the commercial interests of the companies that manufacture the vaccine, and the recommendation of universal vaccination in males. Summary Based on the aforementioned information, we believe that the universal vaccination against HPV in young women is acceptable from an ethical point of view, given the medical advantages it presents.


Related Articles

  • Politicians 'hijack' cancer prevention.  // Nursing Standard;5/9/2007, Vol. 21 Issue 35, p26 

    The article offers views from several nurses in Great Britain on whether girls should be vaccinated against the virus that causes cervical cancer. One practice nurse emphasizes the importance of reviewing a wider program for sexual health promotion before making a decision to make vaccination...

  • At What Age Should We Be Vaccinating for Human Papillomavirus? Paavonen, Jorma // Gynecologic & Obstetric Investigation;Nov2010, Vol. 70 Issue 4, p233 

    Human papillomavirus (HPV) infections cause high disease burden. Primary prevention by vaccination is a major breakthrough. HPV vaccines are well tolerated and safe. Vaccines protect unexposed individuals against high-grade CIN and VIN/VaIN caused by the vaccine HPV types. Vaccines also provide...

  • Introduction of Human Papillomavirus Vaccination in Belgium, Luxembourg and the Netherlands. Arbyn, M.; Simoens, C.; Van Damme, P.; Scharpantgen, A.; Meijer, C. J. L. M.; Beutels, P. // Gynecologic & Obstetric Investigation;Nov2010, Vol. 70 Issue 4, p224 

    Aims: To document progress with human papillomavirus (HPV) vaccine introduction in three closely related European countries, one with organized (the Netherlands) and two with opportunistic cervical cancer screening (Belgium and Luxembourg). Methods: Experts involved in cervical cancer screening...

  • To Vaccinate or Not to Vaccinate … That Is the Question. Fontaine, Dan // Canadian Journal of Pathology;2010, Vol. 2 Issue 4, p23 

    The author discusses the information on the human papillomavirus vaccines and its significance in preventing cervical cancer.

  • Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. Brisson, Marc; Van de Velde, Nicolas; De Wals, Philippe; Boily, Marie-Claude // CMAJ: Canadian Medical Association Journal;8/28/2007, Vol. 177 Issue 5, p464 

    Background: A vaccine against human papillomavirus (HPV) types 6, 11, 16 and 18 is now licensed for use in Canada and many other countries. We sought to estimate the number needed to vaccinate to prevent HPV-related diseases and death. Methods: A cohort model of the natural history of HPV...

  • Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young Women. Sow, Papa Salif; Watson-Jones, Deborah; Kiviat, Nancy; Changalucha, John; Mbaye, Khardiata Diallo; Brown, Joelle; Bousso, Kouro; Kavishe, Bazil; Andreasen, Aura; Toure, Macoumba; Kapiga, Saidi; Mayaud, Philippe; Hayes, Richard; Lebacq, Marie; Herazeh, Marjan; Thomas, Florence; Descamps, Dominique // Journal of Infectious Diseases;Jun2013, Vol. 207 Issue 11, p1753 

    Background. Cervical cancer is a major public health problem for women in sub-Saharan Africa. Availability of a human papillomavirus (HPV) vaccine could have an important public health impact.Methods. In this phase IIIb, double-blind, randomized, placebo-controlled, multicenter trial...

  • Choice of cancer vaccine is branded a missed opportunity by charities. Kmietowicz, Zosia // BMJ: British Medical Journal (International Edition);6/28/2008, Vol. 336 Issue 7659, p1456 

    The article discusses how health charities are criticizing the adoption of the drug Cervarix into national immunisation initiatives in Great Britain. Cervarix, developed by the pharmaceutical firm GlaxoSmithKline is designed to vaccinate women against human papillomaviruses, which can cause...

  • The feasibility of universal HPV vaccination program in Shenzhen of China: a health policy analysis. Chen, Ruirui; Wong, Eliza // BMC Public Health;6/20/2019, Vol. 19 Issue 1, pN.PAG 

    Background: HPV vaccination for the prioritized adolescent girls is well accepted and implemented in developed countries as an effective measure for cervical cancer prevention and control with increasing population-level effectiveness evidence accumulated. This study is to assess...

  • Why Consider Human Papillomavirus Vaccination in Older Women? Poppe, W. A.; Simon, P. H.; De Ridder, M. R. // Gynecologic & Obstetric Investigation;Nov2010, Vol. 70 Issue 4, p237 

    Preventive human papillomavirus (HPV) L1 vaccines are safe and efficient to prevent infection and lesions of vaccine- specific HPV types in women from 15 to 26 years, but also in older age groups. Clearly, public health funds are to be spent to organize programs for vaccination of young...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics